On July 21, 2025, Bruker announced disappointing preliminary results for the second quarter, ended June 30, 2025. The Company disclosed earnings and revenue that both fell well-below expectations and announced an estimated 7% year-over-year organic revenue decline, significantly worse than management previously forecast. Bruker blamed soft demand from academic institutions and a slowdown in biopharma for the weakness in bookings, despite having last quarter “established a floor based on current headwinds” including concerns around academic uncertainty and the threat of biopharma tariffs.
Following this news, Bruker’s stock price fell by $3.74 per share to open at $36.82 per share.
To receive more information, please fill out the form.
